CAJ | 학술논문

目的：观察宫颈病灶中单纯疱疹病毒-2(HSV-2)感染状况，探讨宫颈HSV-2感染与宫颈癌的关联性。方法101例宫颈病变患者中宫颈癌患者46例(癌变组)，宫颈良性疾病55例(对照组)，分别对其宫颈病灶组织和宫颈分泌物进行HSV-2 DNA (实时荧光PCR法)和人乳头瘤病毒(HPV)基因分型(快速导流杂交法)检测。结果宫颈病灶HSV-2 DNA阳性率为10.89%；其中癌变组HSV-2的阳性率为17.39%，对照组为5.45%，两组间差异无统计学意义(P>0.05)。宫颈病灶HPV总阳性率为67.33%，共检测出13种HPV亚型，以16型最多见(45.45%)；癌变组(97.83%)与对照组(41.82%)间比较差异有统计学意义(χ2=34.087，P<0.001)。HSV-2与HPV合并阳性率为9.90%，HSV-2感染的癌变组中HPV阳性率达100%，混合感染的亚型主要为HPV16占75%。结论 HSV-2多与HPV 16亚型合并感染宫颈癌患者，其在宫颈癌演变过程中的潜在影响不能忽视。
목적：관찰궁경병조중단순포진병독-2(HSV-2)감염상황，탐토궁경HSV-2감염여궁경암적관련성。방법101례궁경병변환자중궁경암환자46례(암변조)，궁경량성질병55례(대조조)，분별대기궁경병조조직화궁경분비물진행HSV-2 DNA (실시형광PCR법)화인유두류병독(HPV)기인분형(쾌속도류잡교법)검측。결과궁경병조HSV-2 DNA양성솔위10.89%；기중암변조HSV-2적양성솔위17.39%，대조조위5.45%，량조간차이무통계학의의(P>0.05)。궁경병조HPV총양성솔위67.33%，공검측출13충HPV아형，이16형최다견(45.45%)；암변조(97.83%)여대조조(41.82%)간비교차이유통계학의의(χ2=34.087，P<0.001)。HSV-2여HPV합병양성솔위9.90%，HSV-2감염적암변조중HPV양성솔체100%，혼합감염적아형주요위HPV16점75%。결론 HSV-2다여HPV 16아형합병감염궁경암환자，기재궁경암연변과정중적잠재영향불능홀시。
Objective To observe HSV-2 infection status in cervical lesions,and explore the relationship be-tween cervical HSV-2 infection and cervical cancer. Methods Cervical lesions and cervical secretions were collect-ed from 101 patients with cervical lesion, HSV-2 DNA (real time PCR method) and human papilloma virus (HPV) genotype (flow-through hybridization) were detected. Results The positive rate of HSV-2 DNA in cervical lesions was 10.89%, and that in cancer group and control group was 17.39%and 5.45%, respectively, with no significant dif-ference between the two groups. The positive rate of HPV test in cervical lesions was 67.33%, and 13 subtypes of HPV were found in cervical lesions. The positive rate of the most common subtype of type 16 was 45.45%, and that in cancer group and control group was 97.83%and 41.82%, respectively, with the statistically significant difference be-tween the two groups. (χ2=34.087, P<0.001). The positive rate of HSV-2 merged with HPV was 9.90%. The positive rate of HPV in cancer group of HSV-2 infection was 100%. mixed infections of HPV16 subtype accounted for 75%. Conclusion HSV-2 is more common in co-infected with HPV16 subtype in patients with cervical cancer, and the potential impact of HSV-2 on cervical evolution should not be ignored.